Quark Venture

Alpha9 Theranostics is a biopharma company that focuses on radiotherapeutics for the treatment of solid and hematologic malignancies. The company is creating a strong pipeline of radiopharmaceuticals to target solid and hematologic malignancies. Its systematic approach to radiotherapeutic design is fueled by a toolbox of technologies and chemistries, which offers broad potential for expansion into a multitude of oncology targets. Alpha9 Theranostics was founded in 2019 and is headquartered in Vancouver, Canada.

V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.

Lyndra Therapeutics, Inc. is a biotechnology company that specializes in the development of ultra-long-acting oral medicines. Founded in 2015 and headquartered in Watertown, Massachusetts, the company focuses on creating orally administered dosage forms that can deliver a sustained release of medications for periods ranging from a week to a month while remaining in the stomach. Lyndra's therapeutic initiatives target a variety of conditions, including Alzheimer's disease, cardiovascular and metabolic disorders, psychiatric issues, opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. By enhancing medication adherence and improving health outcomes, Lyndra Therapeutics aims to contribute to lower healthcare costs and better patient care.

Volastra Therapeutics, Inc. is a biotechnology company based in New York that focuses on developing therapies for metastatic cancers. Founded in 2019, the company utilizes a library of organoids derived from metastatic cancer samples to understand tumor spread and create targeted therapeutic strategies aimed at chromosomal instability. By integrating artificial intelligence, bioinformatics, and proprietary imaging techniques, Volastra identifies cancers at higher risk of metastasis, allowing healthcare professionals to select appropriate patients for therapy and improve treatment outcomes. Through its innovative approach, Volastra seeks to advance the understanding and management of metastatic diseases.

CalciMedica, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, specializing in the discovery and development of small molecule drugs aimed at treating autoimmune and inflammatory diseases. Founded in December 2006 by a team of scientists with backgrounds in the field, the company focuses on the specific inhibition of calcium release-activated calcium channels. This innovative approach seeks to modulate the immune response and protect against tissue cell injury, addressing significant unmet medical needs in life-threatening inflammatory conditions for which existing therapies are lacking. CalciMedica's proprietary technology has the potential to offer therapeutic benefits in these challenging areas of healthcare.

V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.

EnClear Therapies, Inc. is a life sciences company based in Newburyport, Massachusetts, focused on developing device-based therapies for neurodegenerative diseases. The company specializes in the delivery and monitoring of cerebrospinal fluid (CSF) and has created a proprietary therapeutic platform aimed at removing toxic proteins from the CSF. EnClear's products are primarily designed to improve the lives of patients suffering from conditions such as Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). By providing innovative solutions in the treatment of these neurological diseases, EnClear Therapies aims to help halt disease progression and extend patient lifespans.

Volastra Therapeutics, Inc. is a biotechnology company based in New York that focuses on developing therapies for metastatic cancers. Founded in 2019, the company utilizes a library of organoids derived from metastatic cancer samples to understand tumor spread and create targeted therapeutic strategies aimed at chromosomal instability. By integrating artificial intelligence, bioinformatics, and proprietary imaging techniques, Volastra identifies cancers at higher risk of metastasis, allowing healthcare professionals to select appropriate patients for therapy and improve treatment outcomes. Through its innovative approach, Volastra seeks to advance the understanding and management of metastatic diseases.

Eyevensys S.A.S. is a Paris-based company that specializes in non-viral gene therapy for ophthalmology. Founded in 2008, it focuses on developing innovative solutions to improve drug delivery methods for ocular diseases. The company utilizes its proprietary Electro-Transfection (ET) technology to administer plasmids to the ciliary muscle, allowing for the sustained release of therapeutic proteins directly into the vitreous, addressing conditions such as uveitis, age-related macular degeneration, and various retinopathies, including central retinal vein occlusion and diabetic retinopathy. Eyevensys aims to overcome the limitations of current treatment options, which often involve invasive procedures like intravitreal injections and surgeries. By enhancing compliance, ocular bioavailability, and tolerability, Eyevensys seeks to create a robust product pipeline that delivers improved clinical outcomes while minimizing the need for frequent and invasive interventions.

Raziel Therapeutics Ltd. is a pharmaceutical company based in Rehovot, Israel, founded in 2012. The company specializes in the development of RZL-012, a novel synthetic small molecule designed for injectable treatment into subcutaneous fat. This treatment leads to fat cell death at the injection site, resulting in a significant and long-lasting reduction in fat tissue. Raziel Therapeutics is engaged in various clinical trials focusing on fat-related conditions and aesthetic applications, aiming to provide effective solutions for obesity and disorders such as Dercum's disease. The innovative approach of Raziel Therapeutics offers healthcare professionals a non-invasive option for achieving substantial fat reduction for their patients.

Raziel Therapeutics Ltd. is a pharmaceutical company based in Rehovot, Israel, founded in 2012. The company specializes in the development of RZL-012, a novel synthetic small molecule designed for injectable treatment into subcutaneous fat. This treatment leads to fat cell death at the injection site, resulting in a significant and long-lasting reduction in fat tissue. Raziel Therapeutics is engaged in various clinical trials focusing on fat-related conditions and aesthetic applications, aiming to provide effective solutions for obesity and disorders such as Dercum's disease. The innovative approach of Raziel Therapeutics offers healthcare professionals a non-invasive option for achieving substantial fat reduction for their patients.

Pi Therapeutics is a discovery-stage biopharmaceutical company aiming to develop a novel cancer drug. The company is financed by a syndicate of Takeda Pharmaceutical Company through its venture group Takeda Ventures Inc., Johnson & Johnson Innovation – JJDC, OrbiMed Israel Partners, Pontifax, and the Israel Innovation Authority, and has operated since March 2015 in the FutuRx biotech accelerator in Ness Ziona, Israel. The company’s mission is to develop novel first-in-class drugs directed against the ubiquitin-proteasome system (UPS), mainly for treatment of cancer.

Lyndra Therapeutics, Inc. is a biotechnology company that specializes in the development of ultra-long-acting oral medicines. Founded in 2015 and headquartered in Watertown, Massachusetts, the company focuses on creating orally administered dosage forms that can deliver a sustained release of medications for periods ranging from a week to a month while remaining in the stomach. Lyndra's therapeutic initiatives target a variety of conditions, including Alzheimer's disease, cardiovascular and metabolic disorders, psychiatric issues, opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. By enhancing medication adherence and improving health outcomes, Lyndra Therapeutics aims to contribute to lower healthcare costs and better patient care.

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative treatments for patients with hematological and musculoskeletal disorders that have significant unmet medical needs. The company's lead product candidate, KER-050, targets low blood cell counts, specifically anemia and thrombocytopenia, in patients with myelodysplastic syndromes and myelofibrosis. Additionally, Keros is advancing KER-047, a small molecule therapy aimed at treating anemia caused by elevated hepcidin levels, as well as fibrodysplasia ossificans progressiva. Another candidate, KER-012, is being developed for conditions related to bone loss, such as osteoporosis and osteogenesis imperfecta, and for pulmonary arterial hypertension. Founded in 2015, Keros Therapeutics is headquartered in Lexington, Massachusetts.

Sitka Biopharma Inc. is a preclinical biotechnology company based in Vancouver, Canada, established in 2013. The company specializes in developing a nanoparticle platform technology aimed at improving drug absorption in challenging tissues. Its primary focus is on oncology, with its lead candidate, STK-01, designed to enhance the effectiveness of intravesical chemotherapy for bladder cancer. This technology addresses significant issues related to limited drug uptake and tolerability in current treatment options. Sitka's innovative approach seeks to deliver higher concentrations of the chemotherapeutic agent docetaxel directly into the bladder wall, which may lead to better treatment outcomes. The company plans to expand its applications to intraperitoneal delivery for ovarian cancer, demonstrating the versatility of its nanoparticle platform in treating localized diseases effectively.

Canary Medical Inc. focuses on developing innovative medical implant and data management devices that facilitate remote patient monitoring and data collection. Founded in 2013 and based in Vancouver, Canada, the company has created the Canary Health Implantable Reporting Processor (CHIRP), a sensor-based device that autonomously gathers medical data without requiring significant patient compliance or physician intervention. In 2021, it launched canturio™te, the first "smart knee" tibial extension, which continuously monitors patient activity and joint performance, transmitting the collected data to the cloud. Canary Medical aims to enhance healthcare outcomes while reducing costs by providing reliable and efficient healthcare data monitoring and analysis. The company is backed by a team of experienced professionals with expertise in medical device design, development, and data informatics.

V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.

ARTMS is a technology developer focused on transforming the production of diagnostic imaging isotopes. The company has created the QUANTM Irradiation System, which supports decentralized and local production of essential medical isotopes such as gallium-68, zirconium-89, technetium-99m, and copper-64. This innovative technology allows for cost-effective, high-yield production using local hospital-based medical cyclotrons, thereby enabling the nuclear medicine industry to better manage supply chain demands and enhance the availability of critical imaging agents. Through its advancements, ARTMS aims to improve access to important diagnostic tools in healthcare.

Bioarray Therapeutics, Inc. is a biotechnology company founded in 2009, initially based in Boston and now located in Farmington, Connecticut. The company focuses on developing proprietary predictive diagnostic tests aimed at improving cancer treatment outcomes. Its primary product is a breast cancer response prediction test that utilizes gene expression profiling to evaluate a patient's likelihood of responding to standard pre-surgery taxane-based chemotherapy. By identifying the most effective treatment options based on genetic markers, Bioarray Therapeutics seeks to move away from the traditional trial-and-error approach in cancer care, enhancing the personalization of treatment for patients.

CathWorks Ltd. is a medical technology company that specializes in enhancing percutaneous coronary intervention (PCI) therapy decisions through its advanced computational science platform. Founded in 2013 and headquartered in Kfar-Saba, Israel, with an additional office in the United States, the company has developed the CathWorks FFRangio, a non-invasive device that provides objective, multi-vessel physiologic measurements. This tool transforms coronary angiography from a subjective visual assessment into an objective decision-making framework based on fractional flow reserve (FFR) metrics. By utilizing sophisticated algorithms to process visual information, CathWorks aims to improve the efficiency of cath lab operations and support healthcare providers in making data-driven clinical decisions.

Sitka Biopharma Inc. is a preclinical biotechnology company based in Vancouver, Canada, established in 2013. The company specializes in developing a nanoparticle platform technology aimed at improving drug absorption in challenging tissues. Its primary focus is on oncology, with its lead candidate, STK-01, designed to enhance the effectiveness of intravesical chemotherapy for bladder cancer. This technology addresses significant issues related to limited drug uptake and tolerability in current treatment options. Sitka's innovative approach seeks to deliver higher concentrations of the chemotherapeutic agent docetaxel directly into the bladder wall, which may lead to better treatment outcomes. The company plans to expand its applications to intraperitoneal delivery for ovarian cancer, demonstrating the versatility of its nanoparticle platform in treating localized diseases effectively.

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of novel drugs targeting rare and ultra-rare genetic diseases caused by nonsense mutations. Founded in 2013, the company is focused on discovering and commercializing ribonucleic acid modulating drug candidates. Its lead investigational product, ELX-02, is currently undergoing Phase 2 clinical trials aimed at treating cystic fibrosis and nephropathic cystinosis in patients with specific nonsense mutations. Eloxx utilizes its advanced technology platform to create oral small molecules that can induce ribosomal readthrough, thereby enabling the production of full-length functional proteins. The company is building a robust pipeline of therapeutic candidates designed to address various genetic disorders, including Duchenne Muscular Dystrophy and Tay-Sachs syndrome, by overcoming the limitations posed by premature stop codons.

PhysIQ, Inc. is a health technology company based in Chicago, Illinois, that specializes in a cloud-based predictive platform for personalized physiology analytics. The company has developed a platform that analyzes multiple data streams to establish individual baseline norms for patients, allowing clinicians to monitor vital signs and detect clinically significant changes. This innovative approach helps manage chronic illnesses by predicting acute medical events before symptoms arise and empowers consumers to take control of their health and fitness. PhysIQ's solution is applicable in both regulated healthcare and unregulated health and fitness markets, and it can be integrated into other patient monitoring devices, enhancing their capabilities. Founded in 2013, PhysIQ was previously known as VGBio, Inc.

PHEMI Systems Corporation specializes in developing a comprehensive privacy, security, governance, and data management system optimized for Microsoft Azure. Founded in 2013 and based in Vancouver, Canada, the company focuses on the healthcare sector, offering the PHEMI Data Privacy Manager. This cloud-based platform addresses the critical need for healthcare organizations to secure, manage, and control access to sensitive information while ensuring compliance with privacy regulations. Built on a privacy-by-design architecture, PHEMI’s software facilitates data sharing and integrates seamlessly with numerous data sources, as well as popular data science and business analysis tools. The platform is designed to scale according to the organization's size and offers a flexible usage-based pricing model.

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of novel drugs targeting rare and ultra-rare genetic diseases caused by nonsense mutations. Founded in 2013, the company is focused on discovering and commercializing ribonucleic acid modulating drug candidates. Its lead investigational product, ELX-02, is currently undergoing Phase 2 clinical trials aimed at treating cystic fibrosis and nephropathic cystinosis in patients with specific nonsense mutations. Eloxx utilizes its advanced technology platform to create oral small molecules that can induce ribosomal readthrough, thereby enabling the production of full-length functional proteins. The company is building a robust pipeline of therapeutic candidates designed to address various genetic disorders, including Duchenne Muscular Dystrophy and Tay-Sachs syndrome, by overcoming the limitations posed by premature stop codons.

Lyndra Therapeutics, Inc. is a biotechnology company that specializes in the development of ultra-long-acting oral medicines. Founded in 2015 and headquartered in Watertown, Massachusetts, the company focuses on creating orally administered dosage forms that can deliver a sustained release of medications for periods ranging from a week to a month while remaining in the stomach. Lyndra's therapeutic initiatives target a variety of conditions, including Alzheimer's disease, cardiovascular and metabolic disorders, psychiatric issues, opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. By enhancing medication adherence and improving health outcomes, Lyndra Therapeutics aims to contribute to lower healthcare costs and better patient care.

Biscayne Pharmaceuticals, Inc. is a biopharmaceutical company based in Miami, Florida, focused on developing therapies that leverage growth hormone-releasing hormone (GHRH) analogs. The company is engaged in creating GHRH antagonists aimed at treating various cancers, including castrate-resistant prostate cancer, and GHRH agonists intended for cardiac repair in patients with heart disease. Additionally, Biscayne Pharmaceuticals is involved in developing drugs for refractory epilepsy and drug-resistant cancer by targeting GHRH receptors, which play a critical role in stimulating growth hormone production for tissue growth and repair. Since its incorporation in 2012, the company has aimed to provide innovative treatments for patients with challenging medical conditions.

Biscayne Neurotherapeutics is a clinical-stage biotechnology company based in Miami, Florida, focused on developing innovative therapies for challenging neurological disorders. The company is advancing its lead compound, BIS-001, aimed at treating refractory forms of epilepsy, including complex partial seizures and conditions like Dravet syndrome. BIS-001 is a synthetic version of huperzine A, an acetylcholinesterase inhibitor known for its ability to penetrate the brain effectively, offering a distinct mechanism of action. Biscayne Neurotherapeutics is supported by a seasoned executive team with a strong background in drug development, as well as a group of esteemed scientific advisors specializing in seizure and central nervous system disorders. The firm is part of the expanding biomedical sector in South Florida, positioning itself to contribute significantly to the treatment landscape for epilepsy and other neurological conditions.

Microbion Corporation is a biopharmaceutical company focused on developing therapeutics for resistant and difficult-to-treat infections. Founded in 1982 and headquartered in Bozeman, Montana, with an additional office in Vancouver, Canada, the company specializes in bismuth-thiols, which are designed to prevent microbial biofilms from forming on implanted medical devices and to manage biofilms in various infectious diseases. Microbion's product pipeline includes treatments for chronic and acute wound infections, particularly those related to diabetic foot ulcers, orthopedic implant-related infections, and other chronic wounds. The company also addresses the challenges posed by antibiotic-resistant microbes, including methicillin-resistant staphylococcus aureus, and aims to reduce infections associated with military wounds.

SQZ Biotech is a clinical-stage biotechnology company focused on developing innovative cell therapies for patients facing cancer, infectious diseases, and other serious health conditions. Utilizing its proprietary CellSqueeze technology, SQZ Biotech can deliver a variety of materials into diverse patient cell types, enabling the engineering of therapies that address a wide array of clinical challenges. The company aims to create well-tolerated cell therapies that not only enhance therapeutic benefits but also improve the overall patient experience compared to traditional cell therapy methods. Through a combination of internal research initiatives and external collaborations, SQZ Biotech is advancing a new generation of cellular therapies aimed at both immune activation and immune suppression.

MSI Methylation Sciences, Inc. is a biotechnology company based in Canada that focuses on developing oral and small molecule therapies for the adjunctive treatment of Major Depressive Disorder (MDD). Founded in 2007, the company is known for its product Strada, an orally administered therapy designed to alleviate symptoms of depression in MDD patients. Additionally, MSI develops S-Adenosyl Methionine, a prescription drug that serves as a dietary supplement. The company aims to reduce drug development risk while providing effective treatment options based on ademetionine, a naturally occurring molecule crucial for various biochemical processes in the body.

Sitka Biopharma Inc. is a preclinical biotechnology company based in Vancouver, Canada, established in 2013. The company specializes in developing a nanoparticle platform technology aimed at improving drug absorption in challenging tissues. Its primary focus is on oncology, with its lead candidate, STK-01, designed to enhance the effectiveness of intravesical chemotherapy for bladder cancer. This technology addresses significant issues related to limited drug uptake and tolerability in current treatment options. Sitka's innovative approach seeks to deliver higher concentrations of the chemotherapeutic agent docetaxel directly into the bladder wall, which may lead to better treatment outcomes. The company plans to expand its applications to intraperitoneal delivery for ovarian cancer, demonstrating the versatility of its nanoparticle platform in treating localized diseases effectively.